---
title: "Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan"
description: "Nomura expects WuXi AppTec's revenue in Q4 2025 to grow by 9.2% to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion. For the fiscal year 2026, revenue is projected to grow by 16"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275694444.md"
published_at: "2026-02-12T03:21:34.000Z"
---

# Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan

> Nomura expects WuXi AppTec's revenue in Q4 2025 to grow by 9.2% to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion. For the fiscal year 2026, revenue is projected to grow by 16% to RMB 52.6 billion, and profit is expected to increase by 3% to RMB 19.6 billion. Revenue from TIDES and later-stage development and manufacturing businesses is expected to grow by 55% and 10%, respectively. The target price has been raised from HKD 132.8 to HKD 157.07, and the A-share target price has been increased from RMB 120.85 to RMB 142.93, both with a "Buy" rating

Nomura's research report indicates that based on WuXi AppTec (02359.HK) announcing a positive profit forecast, it is expected that revenue in the fourth quarter of 2025 will grow by 9.2% year-on-year to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion.

Looking ahead to the fiscal year 2026, the company’s revenue is expected to grow by 16% year-on-year to RMB 52.6 billion, exceeding market expectations of RMB 51.1 billion, due to strong performance in the chemical business; profit is expected to grow by 3% year-on-year to RMB 19.6 billion. The year-on-year growth rate for continuing operations is 21%.

By business segment, the bank expects that in fiscal year 2026, revenue from TIDES and late-stage development and manufacturing will grow by 55% and 10% year-on-year, reaching RMB 17.1 billion and RMB 21.6 billion, respectively. The growth in TIDES business is based on sustained demand and supported by the company's 100,000-liter large-scale functional production capacity.

The bank has raised the target price for WuXi AppTec's H shares from HKD 132.8 to HKD 157.07, and the target price for WuXi AppTec's A shares (603259.SH) from RMB 120.85 to RMB 142.93, both with a "Buy" rating

### Related Stocks

- [159892.CN - ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/159892.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [520500.CN - Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/520500.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [603259.CN - WuXi AppTec](https://longbridge.com/en/quote/603259.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [02359.HK - WUXI APPTEC](https://longbridge.com/en/quote/02359.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows | BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows | [Link](https://longbridge.com/en/news/276436772.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.